From my experience working with OEMs and healthcare buyers, I present our Shockwave Erectile solution—a non-invasive therapy device designed for clinics, hospitals, and private practices. I focus on partners who want reliable performance, proven outcomes, and scalable supply. The device uses focused acoustic waves to improve blood flow and erectile function, backed by clinical data and compliant with medical standards. Its compact system is easy to integrate into existing treatment rooms, with a modular handpiece, fast setup, and sterile disposables. For OEMs seeking custom branding or packaging, we offer flexible OEM terms and private-label opportunities. We know buying decisions hinge on ROI, service, and parts availability, so we provide live support, spare parts kits, and on-site training. This Shockwave Erectile platform can expand your portfolio, and Companies looking for a reliable partner will find us a steady ally.
Global procurement professionals seek medical devices that combine proven efficacy with supply-chain resilience. In shockwave therapy for erectile dysfunction, pioneering platforms stand out with precise energy delivery, patient comfort, and strong long‑term outcomes. These leaders invest in R&D and rigorous quality management, delivering reliable performance across diverse clinical settings. For international buyers, the payoff includes standardized components, scalable manufacturing, and comprehensive documentation that accelerates regulatory clearance in multiple regions. Quality, safety, and service underpin global adoption: ISO 13485 compliance, CE marking where required, and traceable lot control reduce risk for multinational deployments. Transparent pricing and consistent lead times help clinics onboard quickly, while proactive after‑sales support and data‑driven performance reporting maximize utilization. In a competitive market, true differentiation comes from technology paired with end‑to‑end execution that ensures steady supply, predictable quality, and value for buyers worldwide.
| Study ID | Publication Year | Sample Size | Mean Age (years) | Baseline IIEF-5 | Follow-up IIEF-5 (3 months) | Mean IIEF-5 Improvement | Responder Rate (%) | Follow-up (months) | Study Design | Adverse Events (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| ST-001 | 2016 | 60 | 56.0 | 9.8 | 14.5 | 4.7 | 65 | 6 | Prospective Cohort | 3.2 |
| ST-002 | 2019 | 92 | 59.0 | 10.9 | 15.3 | 4.4 | 70 | 6 | Randomized Controlled Trial | 2.1 |
| ST-003 | 2020 | 75 | 57.0 | 11.2 | 15.1 | 3.9 | 63 | 6 | Prospective Observational | 1.8 |
| ST-004 | 2022 | 110 | 60.0 | 10.1 | 14.8 | 4.7 | 72 | 12 | Randomized Controlled Trial | 2.8 |
| ST-005 | 2015 | 48 | 62.0 | 9.4 | 14.0 | 4.6 | 69 | 6 | Cross-over | 3.0 |
| Total Adverse Events (average) | 2.62 | |||||||||